Created at	Source	Raw Value	Validated value
May 2, 2022, 3:30 p.m.	eu	The primary study endpoint is the proportion of patients requiring IMV (or ECMO) by day 28 [NIAID-OS 7]	The primary study endpoint is the proportion of patients requiring IMV (or ECMO) by day 28 [NIAID-OS 7]